ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR
This site is part of the Siconnects Division of Sciinov Group
This site is operated by a business or businesses owned by Sciinov Group and all copyright resides with them.
ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR
27MAR, 2023
Funding will support the development of Aurase Wound Gel and progress toward further Phase II clinical trials of innovative wound debriding enzyme
SOLASCURE Ltd (SolasCure), a biotechnology company developing a hydrogel containing a recombinant enzyme derived from maggots which aims toaccelerate wound debridement, has announced the completion of its GBP 10.9m (c. USD 13.3m)Series B investment round. The funding round was led by Seneca Partners and also included industryveterans, institutional venture and strategic investors, including BRAIN Biotech AG, EVA Pharma,Jonathan Milner, and Wealth Club.
SolasCure’s first investigational product, Aurase Wound Gel, a hydrogel containing an enzyme clonedfrom medical maggots which aims to accelerate wound debridement, is due to enter further Phase IIefficacy-supporting trials. The next phase of trials will include a larger and more diverse patient groupcompared to the Phase IIa safety study. The Company is hopeful that the results will continue todemonstrate how its innovative technology supports healthcare professionals treating patients with chronic wounds.
The pre-clinical trial results of SolasCure’s Aurase Wound Gel, published in the International WoundJournal, showed preliminary evidence that supports its new enzymatic debridement product for use inchronic wounds. The enzyme is shown to have a good safety profile, both locally and systemically, which opens up a large therapeutic window. This has permitted SolasCure under regulatory review to test the enzyme on real patients with ulcers. SolasCure recently completed its CLEANVLU proof-of-concept first-in-man Phase IIa safety study examining the use of Aurase Wound Gel in chronic venous leg ulcer subjects. Results are now being collated and analyzed, and more information will be available in the near future.
Dr Sam Bakri, Founder & CEO, SolasCure, said: “We would like to thank investors in our Series Bround for continuing to support us as we progress our clinical development programme and focus ondeveloping the efficacy of Aurase Wound Gel. We are excited to be working with such an experiencedteam, whose specialist knowledge is greatly valued in our mission to support healthcare professionalswith wound care products that significantly improve outcomes for patients with chronic wounds.”
Matthew Currie, Investment Director, Seneca Partners, added: “We are delighted to continue tosupport SolasCure through its latest funding round, following the impressive progress and positiveresults to date shown by the Aurase Wound Gel. We recognise great potential in the Company andsupport its mission to develop a potentially disruptive medical product that could displace its maincompetitor and achieve global commercial market success.”
SolasCure was founded in 2017 as a spin-off from BRAIN Biotech AG, a leading German biotechcompany focused on harnessing biological diversity to develop innovative solutions.
Adriaan Moelker, CEO, BRAIN Biotech, commented: “We have been very pleased with the
progress made by SolasCure during the clinical trial towards bringing this truly meaningful solution topatients. Our commitment to the Company is unchanged and we were happy to participate in thelatest funding round.”